“I always like to be competitive, and so for me, being first to market is critical. We meet future patients to talk to about their needs and stuff, and so when you see that, and you talk to these families and the caregivers, you want to race as fast as you can to provide them assistance in their daily life.”

Most people have heard of Elon Musk’s implantable brain chip called Neuralink, but there are other players involved that are also working towards similar goals.

SEE: Elon Musk’s Neuralink Will Attempt To Emulate Jesus’ Miracles Of Restoring Sight To The Blind, Make The Lame Walk, And Raising The Dead

Last year a lesser-known company called Synchron burst onto the scene when their brain chip – which offers similar functionality as the Neuralink – when they were able to beat Neuralink to the punch by entering the first stage of live human trials. The Synchron implants can connect to the user’s smartphone and is touted as being able to restore some bodily functionality that may have been lost or damaged.

SEE: Biotech Company Synchron Begins First Live Trials To Test A Chip In The Brain That Connects To Smartphones

But now it has been revealed by mainstream media press that some of the richest men in the world, Jeff Bezos, the founder and former CEO of Amazon, and the founder of Microsoft and philanthropist Bill Gates, are also funding the Synchron implants.

CNBC has more on this (select excerpts) investment and what the chip can do:


In a Brooklyn lab stuffed with 3D printers and a makeshift pickleball court, employees at a brain interface startup called Synchron are working on technology designed to transform daily life for people with paralysis.

The Synchron Switch is implanted through the blood vessels to allow people with no or very limited physical mobility to operate technology such as cursors and smart home devices using their mind. So far, the nascent technology has been used on three patients in the U.S. and four in Australia.

I’ve seen moments between patient and partner, or patient and spouse, where it’s incredibly joyful and empowering to have regained an ability to be a little bit more independent than before. It helps them engage in ways that we take for granted.

Synchron CEO Tom Oxley told CNBC in an interview.

Founded in 2012, Synchron is part of the burgeoning brain-computer interface, or BCI, industry. A BCI is a system that deciphers brain signals and translates them into commands for external technologies. Perhaps the best-known name in the space is Neuralink, thanks to the high profile of founder Elon Musk, who is also the CEO of Tesla, SpaceX and Twitter.

But Musk isn’t the only tech billionaire wagering on the eventual transition of BCI from radical science experiment to flourishing medical business. In December, Synchron announced a $75 million financing round that included funding from the investment firms of Microsoft co-founder Bill Gates and Amazon founder Jeff Bezos.

‘More Scalable’

In August 2020, the Food and Drug Administration granted Synchron the Breakthrough Device designation, which is for medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions. The following year, Synchron became the first company to receive an Investigational Device Exemption from the FDA to conduct trials of a permanently implantable BCI in human patients. 

Synchron is enrolling patients in an early feasibility trial, which aims to show that the technology is safe to put in humans. Six patients will be implanted with Synchron’s BCI during the study, and Chief Commercial Officer Kurt Haggstrom said the company is currently about halfway through. 

The company has no revenue yet, and a spokesperson said Synchron isn’t commenting on how much the procedure will eventually cost.

While many competitors have to implant their BCIs through open-brain surgery, Synchron relies on a less invasive approach that builds on decades of existing endovascular techniques, the company said.

Synchron’s BCI is inserted through the blood vessels, which Oxley calls the “natural highways” into the brain. Synchron’s stent, called the Stentrode, is fitted with tiny sensors and is delivered to the large vein that sits next to the motor cortex. The Stentrode is connected to an antenna that sits under the skin in the chest and collects raw brain data that it sends out of the body to external devices. 

Peter Yoo, senior director of neuroscience at Synchron, said since the device is not inserted directly into the brain tissue, the quality of the brain signal isn’t perfect. But the brain doesn’t like being touched by foreign objects, Yoo said, and the less invasive nature of the procedure makes it more accessible.

There’s roughly about 2,000 interventionalists who can perform these procedures. It’s a little bit more scalable, compared to, say, open-brain surgery or burr holes, which only neurosurgeons can perform.

Yoo told CNBC.

For patients with severe paralysis or degenerative diseases such as amyotrophic lateral sclerosis, or ALS, Synchron’s technology can help them regain their ability to communicate with friends, family and the outside world, whether through typing, texting or even accessing social media. 

Patients can use Synchron’s BCI to shop online and manage their health and finances, but Oxley said what often excites them the most is text messaging. 

Losing the ability to text message is incredibly isolating. Restoring the ability to text message loved ones is a very emotional restoration of power.

Oxley said.

In December 2021, Oxley handed over his Twitter account to a patient named Philip O’Keefe, who has ALS and struggles to move his hands. About 20 months earlier, O’Keefe was implanted with Synchron’s BCI. 

“hello, world! Short tweet. Monumental progress,” O’Keefe tweeted on Oxley’s page, using the BCI. 

Haggstrom said his company’s funding will help accelerate Synchron’s product development and push it toward a pivotal clinical trial that would bring the company closer to commercialization.

Khosla Ventures partner Alex Morgan, who led an earlier financing round, said that while Synchron’s device may seem like something out of science fiction, it’s grounded in “real science” and is already making a significant difference in patients’ lives. 

Synchron is actually helping people as of right now, today. That, to me, is really exceptional.

He said in an interview
Synchron’s brain-computer interface, The Stentrode™ Endovascular Electrode Array and Implantable Receiver Transmitter Unit. Courtesy: Synchron

In January, the medical journal JAMA Neurology published the peer-reviewed, long-term safety results from a trial of Synchron’s BCI system in Australia. The study found that the technology remained safe and didn’t deteriorate in signal quality or performance over a 12-month period.

That was a huge publication for us.

Haggstrom said.

Haggstrom said commercialization is key for all the players in the industry.

I always like to be competitive, and so for me, being first to market is critical. We meet future patients to talk to about their needs and stuff, and so when you see that, and you talk to these families and the caregivers, you want to race as fast as you can to provide them assistance in their daily life.

Haggstrom said.

AUTHOR COMMENTARY

Sure, it’ll start out addressing health problems and promote “convenience,” (like all the other invasive technologies are promoted as), but then it will used for such much more; like connecting to the internet of things (IoT), the 6G framework, metaverse, and so on. Ultimately this is another big move closer towards the eventual mark of the beast.

[16] And he causeth all, both small and great, rich and poor, free and bond, to receive a mark in their right hand, or in their foreheads: [17] And that no man might buy or sell, save he that had the mark, or the name of the beast, or the number of his name. [18] Here is wisdom. Let him that hath understanding count the number of the beast: for it is the number of a man; and his number is Six hundred threescore and six.

Revelation 13:16-18

[7] Who goeth a warfare any time at his own charges? who planteth a vineyard, and eateth not of the fruit thereof? or who feedeth a flock, and eateth not of the milk of the flock? [8] Say I these things as a man? or saith not the law the same also? [9] For it is written in the law of Moses, Thou shalt not muzzle the mouth of the ox that treadeth out the corn. Doth God take care for oxen? [10] Or saith he it altogether for our sakes? For our sakes, no doubt, this is written: that he that ploweth should plow in hope; and that he that thresheth in hope should be partaker of his hope. (1 Corinthians 9:7-10).

The WinePress needs your support! If God has laid it on your heart to want to contribute, please prayerfully consider donating to this ministry. If you cannot gift a monetary donation, then please donate your fervent prayers to keep this ministry going! Thank you and may God bless you.

CLICK HERE TO DONATE

1 Comment

  • I wanna make sure I’m part of the Bride of Christ and I wanna be part of it so badly! I’ve been reading the King James Bible – a couple chapters here and there, I’m repenting of my sins, I’m singing the old hymns, and asking God to forgive me of my sinful wicked past and to help me.

    Brothers and sisters in Christ, we are about to depart from this evil world, and I can’t wait!

    Jacob,
    The oil in the lamps with the virgins, I understand that’s addressed to the Jews, but does it make sense to consider oil in our lamps for us as the King James Bible?

Leave a Comment

×